The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have......
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of...
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of...
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by...
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, wea......
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Histor......
Market Outlook The most important clinical distinction in the first-line...
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologo......
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and...
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest sur......
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of...
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into...
Treatment Sequencing provides disease-specific, sequential treatment patterns...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing an......
Myelodysplastic syndromes (MDS) is a heterogeneous collection of hematopoietic...
Myelodysplastic syndromes (MDS) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression......
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven si......
The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the ten-......
Chronic myeloid leukemia is a slow progressive tumor, characterized by...
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BC......
Market Outlook: Despite advancements in the treatment landscape for first-...
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvi......
The chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)...
The chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) markets are becoming incr......
Treatment Sequencing provides disease-specific, sequential treatment patterns in...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis......
Venclexta (Wave 3) is the third in a multiwave series designed to track...
Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukem......
DRG Epidemiology's coverage of multiple myeloma comprises epidemiological...
DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of mu......
DRG Epidemiology's coverage of multiple myeloma comprises epidemiological...
DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of mu......
